Characteristics of clinical trials of new oncology drugs approved in China
Cancer · 2024
DOI: 10.1002/cncr.35106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, 2024. Verfasst von Jing Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrativ…. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Zhuhai University of Macau Science and Technology Research Institute, The University of Macau, The Science and Technology Development Fund of Macau Special Administrative Region.
Abstract (Originalsprache)
Background
Since reforms were introduced to incentivize drug innovation in 2015, the Chinese pharmaceutical market has experienced unprecedented prosperity, with more new drugs than ever before, especially anticancer treatments. In 2021, Chinese regulatory agencies issued the new guideline for clinical research and development of antitumor drugs, triggering a series of responses on the drug market. Limited research has outlined the nature of the original new drugs in China to understand the dynamic response of the market.
Methods
The objective of this article was to map the clinical development of approved new oncology drugs in China from 2015 to 2021 and differed from previous studies by focusing on original new drugs, using the United States as a benchmark, and elaborating the endogenous features of clinical trials.
Results
Clinical trials conducted in China have risen to a level similar to that of the United States in many aspects of trial design, but there is still distance between the implementation and operational details of clinical trials. In the meantime, China has made significant breakthroughs in drug approval. Greater than 60% of novel anticancer drugs in China received accelerated approved for their first listing. Approximately 90% of the pivotal clinical trials supporting initial drug approval used surrogate measures as end points, and one half were nonrandomized or did not have a control group. However, duplicate development without evidence of a clinical advantage compared with current therapies was widely observed.
Conclusions
By presenting a multidimensional landscape of clinical trials and approvals in the real world, this review allows interested researchers, developers, and even regulators to understand what has been done and what should be done next in anticancer drug development in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region, China.
- School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, China.
- DPM, Faculty of Health Sciences, University of Macau, Macao Special Administrative Region, China.
- Centre for Pharmaceutical Regulatory Sciences, University of Macau, Macao Special Administrative Region, China.
ORCID-Profile: Yuan-Jia Hu
Förderung
- Zhuhai University of Macau Science and Technology Research Institute
- The University of Macau
- The Science and Technology Development Fund of Macau Special Administrative Region
Zitieren
APA
Yang, J., Yang, J., & Hu, Y. J. (2024). Characteristics of clinical trials of new oncology drugs approved in China. Cancer. https://doi.org/10.1002/cncr.35106
Vancouver
Yang J, Yang J, Hu YJ. Characteristics of clinical trials of new oncology drugs approved in China. Cancer. 2024. doi:10.1002/cncr.35106
BibTeX
@article{Yang2024,
author = {Yang, Jing and Yang, Ji and Hu, Yuan-Jia},
title = {Characteristics of clinical trials of new oncology drugs approved in China},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35106}
}
EUVIMED